VALUING THE FUTURE OF MOLECULAR DIAGNOSTICS HYATT REGENCY, PHOENIX NOVEMBER 13, 2013

Transcription

1 VALUING THE FUTURE OF MOLECULAR DIAGNOSTICS HYATT REGENCY, PHOENIX NOVEMBER 13, 2013

2 SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our partner model and the ability of our partners and installed base to drive future growth; the ability of our technology to enhance productivity and efficiency; our financial position and anticipated long-term revenue growth; our business model, the markets we are targeting, market segmentation, expected growth of such markets, and the ability of our products to address those markets; sales of our products, their technical capabilities, and the anticipated market size and acceptance, demand and regulatory environment and approvals therefor; our direct sales efforts and transition from distributors for sales of our molecular diagnostic assays, our system placements sales; our system and assay product pipeline and anticipated timelines for regulatory approvals and market releases, including for our next generation multipexing technology and Project ARIES instrumentation and assays; market opportunity for Project Aries and Aries v2; functionality and benefits of Project Aries and Aries v2 and competitive position; development and growth of our LDT strategy, growth of our business in specialty markets, including biothreat, and future opportunities in those markets; our ability to drive growth through investment in R&D and focus on operating leverage and managing operating costs; our long term financial targets; our key steps and strategies for growth; our strategic outlook and growth plan for our business for 2013 and beyond; operational trends, including those related to sales of systems, assays, consumables, and royalty revenues; competitive threats and products offered by other companies; the company s market position versus competitive threats; the impact of the Company acquisitions; international expansion and market opportunities; our business outlook, financial targets and projections about revenues, cash flow, system shipments, expenses and market conditions, and their anticipated impact on Luminex for 2013 and beyond; and, any statements of the plans, strategies and objectives of management for future operations. These forward looking statements speak only as of the date hereof and are based on our current beliefs and expectations and are subject to known or unknown risks and uncertainties some of which are beyond our control that could cause actual results or plans to differ materially and adversely from those anticipated in the forward looking statements. Factors that could cause or contribute to such differences are detailed in our annual, quarterly, or other filings with the Securities and Exchange Commission. We undertake no obligation to update these forward looking statements. Also, certain non-gaap financial measures as defined by SEC Regulation G, may be covered in this presentation. To the extent that any non-gaap financial measures are covered, a presentation of and reconciliation to the most directly comparable GAAP financial measures will be included in this presentation may be available on our website at in accordance with Regulation G.. 2 Copyright 2012 Luminex Corporation

3 AGENDA Welcome Harriss Currie Strategic Overview Patrick Balthrop ARIES Unveiling Expanding Opportunities in Molecular Diagnostics Closing Comments Jeremy Bridge-Cook, Ph.D. Russell W. Bradley Patrick Balthrop Question and Answer 3 Copyright 2012 Luminex Corporation

4 STRATEGIC OVERVIEW PATRICK BALTHROP PRESIDENT AND CEO

5 OUR OBJECTIVE TODAY Luminex will Span the laboratory customer s multiplexing needs Deliver high value solutions, which are unique and differentiated Advance our leadership position Fulfill our customers scientific mission faster, better, high quality results as cost-effectively as possible 5 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

6 LUMINEX INVESTMENT THESIS One of a kind platform technologies - Multiple products - Unmatched installed base Leadership Position in High Growth Markets Track Record of Innovation, Execution, New Products Compelling, Exciting Pipeline as Near Term Catalyst - Next generation multiplexing technology - Expected 2014 commercial launch of Project ARIES - ARIES platform product line, including ARIES v2 - ARIES menu expansion Consistent Above Market Growth and Excellent Financial Position - 70% gross margins 10 year average CAGR 20% 6 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

7 UNIQUE, PROPRIETARY PLATFORMS AND LARGE INSTALLED BASE CAGR = 20% = 13% = 16% 4,979 5,894 6,767 7,700 8,678 9,659 10,410 3, YTD 3Q Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

8 STRONG GROWTH SEGMENTS Integration; Real Time and Multiplexing Next Generation Multiplexing Technology Next Generation Molecular Dx: ARIES + Assays GROWTH LDT Capabilities: xmap & xtag MultiCode: Portfolio Expansion First Mover: xtag & IVD Mol v Dx Multiplexing xmap Technology & Strategic Partnerships MARKET OPPORTUNITY 8 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

9 COMPARISON, MULTIPLEX TECHNOLOGIES 9 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

10 MULTIPLEXING MARKET POSITION FLEXIBLE PLATFORMS 500-Plex 100-Plex MULTIPLEXING CAPABILITIES GNMK BioFire NSPH 50-Plex MAGPIX Launched 2010 Luminex 200 Launched 2005 FLEXMAP 3D Launched 2009 SYSTEM THROUGHPUT 10 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

11 INNOVATION, EXECUTION, NEW PRODUCTS 1 st CF Test Acquisition FLEXMAP 3D Acquisition GPP FDA Cleared ARIES V Luminex 200 RVP FDA Cleared MAGPIX Launch Acquisition Direct Sales Force ARIES Launch, Next Generation Multiplexing 11 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

12 SOLID POSITIONING IN A COMPETITIVE MARKET PLACE WILL DRIVE SUCCESS No 100% Market Share Need Critical Mass -First mover advantage -Menu matters -Strategic strength spanning plex range High GM%/Low Manufacturing Cost is Crucial -Reimbursement trends are clear -Ongoing investment required 12 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

13 SOLID POSITIONING IN A COMPETITIVE MARKET PLACE WILL DRIVE SUCCESS Solution: Address Lab s Scarcity of Resources -Historical precedent: immunoassay, clinical chemistry, etc. Scarcity: Highly Trained Personnel -LDT's comprise majority of Mol Dx tests today -LDT capability not enough; must be streamlined workflow Scarcity: Bench Space -Most acute in Molecular Diagnostics -1:1 ratio unsustainable 13 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

14 CONSISTENT GROWTH * 3 Year Organic Growth LMNX QDEL BIO TMO QGEN CPHD 5 Year Organic Growth 21% 1% 7% 3% 10% 21% 10 Year Organic Growth 29% 6% 9% 5% 10% 35% * Source: SEC Filings, as of Oct Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

15 LUMINEX EXPANDING MARGINS AND PROFITABILITY 80% Gross Margin 70% 66.5% 67.9% 68.1% 70.4% 60% 50% 40% 57.5% 48.4% 41.0% LMNX Peer Avg.* Mol Dx Peer Avg.** Source: SEC Filings, as of Oct 2013 * QDEL, BIO, TMO, QGEN, CPHD, GNMK ** CPHD, GNMK 15 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

16 LUMINEX EXPANDING MARGINS AND PROFITABILITY EBIT Margin 15.0% 8.0% 11.2% 10.9% 5.0% -5.0% -1.1% 3.2% LMNX Peer Avg % -11.6% Source: SEC Filings, as of Oct Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

17 STRATEGIC FOCUS ON MIX TO DRIVE GROSS MARGINS 2004: $36M Revenue 2012: $203M Revenue 13% 25% 9% 53% System Consumables SVC/Other Royalties 37% 15% 24% System Consumables SVC/Other Royalties Assays 15% 9% 17 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

18 COMPELLING PIPELINE AND CATALYSTS Next Generation Multiplexing Highly streamlined workflow Minimal hands on time High volume labs Project ARIES, 2H 2014 Real-time PCR segment projected > $7B 1 by 2017, double digit growth Sample-to-answer 5 assays at/near launch LDT compatible Minimal inches linear bench space Project ARIES Next Generation and Extensions Development underway Real-time plus multiplexing Sample-to-answer Uses proven technologies 1 - Source: Market Diagnostics International (MDxI); Kalorama 2013 Report on Molecular Diagnostics and internal estimates 18 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

19 ARIES UNVEILING JEREMY BRIDGE- COOK, PH.D SENIOR VP, RESEARCH AND DEVELOPMENT

20 PROJECT ARIES 20 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

21 PROJECT ARIES Next-generation sample-to-answer platform that simplifies IVD & LDT testing Established molecular labs and labs that are new to molecular testing IVD assays - moderate complexity, run with little training LDT assays designed by moleculartrained staff but run by technicians with no specialized training Centralized labs can install ARIES in their satellite labs for rapid testing 21 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

22 EXTREMELY POSITIVE CUSTOMER RESPONSES TO ARIES Early customer experience testing has been extremely positive Customers Responses: A Sample-to-answer system like this one will be a huge benefit for our lab. Every lab has labor constraints that ARIES will help alleviate. ARIES is very attractive because it will minimize the hands-on time technicians spend on testing, so they can do more meaningful work. We love the LDT capability. Being able to create LDTs that are sample-to-answer, like the IVD tests, and just as easy to run is a MAJOR advantage for ARIES. 22 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

23 ARIES SIMPLIFIES WORKFLOW 1. Pipette Sample into Cassette 2. Insert Cassette into Magazine 3. Insert Magazine into Instrument 23 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

24 ARIES SYSTEM: KEY DIFFERENTIATORS VS. CURRENT ALTERNATIVES Footprint Narrowest footprint of any sample-to-answer platform Touchscreen integrated into the system Multiple instruments can be run side by side 24 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

25 ARIES SYSTEM: KEY DIFFERENTIATORS VS. CURRENT ALTERNATIVES 2. Lab Menu Consolidation Five IVD assays at launch Multiple IVD assays per year thereafter Typical molecular lab test menu at teaching hospitals include dozens to hundreds of LDTs - Consolidated onto either ARIES or xmap - ARIES LDTs can be exported to satellite labs; no need for skilled technicians 25 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

26 ARIES SYSTEM: KEY DIFFERENTIATORS VS. CURRENT ALTERNATIVES 3. Laboratory Efficiency Simple operation and minimal hands on time frees up technicians LIS integration streamlines patient result reporting Universal assay conditions enable up to 12 different tests to be run simultaneously Random batch design provides run flexibility, capacity & turnaround time 26 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

27 ARIES SYSTEM: KEY DIFFERENTIATORS VS. CURRENT ALTERNATIVES 4. Improved Patient Care Sample to answer workflow and simple operation eliminates user error User error is the largest single source of patient misdiagnoses Patient data transferred automatically Test run linked to patient by barcode MultiCode RTx double discrimination = best-in-class assay performance 27 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

28 ARIES TARGET MARKETS Initial menu focused on infectious disease testing Largest market in MDx Growing at 8% CAGR Potential market for first five ARIES assays = $770M Future markets of interest: Oncology Companion Diagnostics/ Personalized Medicine Non-diagnostic markets (Biodefense, Food Safety, etc.) $ in Billions $8.0 $6.0 $4.0 $2.0 $ Infectious Diseases Oncology Prenatal Pharmacogenomics CAGR 8% Blood Screening Tissue Typing Inherited Disease Other Source: Market Diagnostics International (MDxI); Kalorama 2013 Report on Molecular Diagnostics and internal estimates 28 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

29 LAUNCH MENU & TIMELINE ARIES global launch in 2H 2014 Initial launch menu will include 5 IVD assays, and be compatible with a broad range of LDT reagents A combination of differentiated and workhorse assays - Clostridium difficile - Herpes Simplex Virus 1&2 - Flu A/B/RSV - IVD Assay #4 - IVD Assay #5 In active development; will be announced in 2014 Assays with current CPT codes and strong reimbursement 29 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

30 INCREASING SIMPLICITY AND FLEXIBILITY FOR CLOSTRIDIUM DIFFICILE TESTING Luminex C. difficile test will have no up-front manual processing steps Only company able to offer complete solution (GPP panel & stand-alone C. difficile) - Workflow 1: GPP up front; C. diff to confirm positives - Workflow 2: C. diff up front on inpatients; GPP on negatives & all outpatients Luminex Strategy: Offer full product line to suit all customers needs 30 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

31 INTRODUCING THE FIRST SAMPLE-TO-ANSWER HERPES SIMPLEX VIRUS 1&2 ASSAY Luminex was the first to obtain FDA clearance on HSV1/2 molecular realtime assay Menu differentiator currently no sample-to-answer molecular HSV1/2 assay on the market First assay in the women s health category, with more to follow - Patients want rapid results not available today Will be used to gain the first clearance of the ARIES system 31 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

32 FAST FLU A/B/RSV ASSAY COMPLEMENTARY WITH EXISTING RVP PRODUCT LINE Three respiratory viruses most important for critical care Large central labs need rapid assay throughout lab network Complementary with existing RVP product line and customer base - Workflow 1: RVP on in-patients, Flu A/B/RSV on out-patients - Workflow 2: RVP in central lab, Flu A/B/RSV in satellite labs for rapid results Only company offering sample-to-answer criticalneed flu panel and comprehensive symptombased panel 32 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

33 MAINTAINING COMPETITIVE POSITION WITH EXISTING CUSTOMER BASE BioFire High GenMark Dx Nanosphere xtag/xmap Plex Range Low Cepheid Project ARIES Abbott BD Hologic Roche * Throughput from base model Low Throughput * 33 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science High

34 NEXT GENERATION xtag PLATFORM SIMPLIFYING WORKFLOW WITHOUT COMPROMISING PERFORMANCE OR THROUGHPUT Pipette samples into plate Seal reaction vessels Transfer to thermal cycler Transfer to MAGPIX Simplified Workflow Low Contamination Risk Rapid Turnaround Time High Plex and Throughput 34 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

35 NEXT GENERATION xtag PLATFORM UPDATE The next generation RVP product is in development Achieved goal of combining all reagents required to run a bead-based respiratory panel into one master mix - Critical feature of maintaining high throughput has been achieved Performance of the product is favorable, and feedback from customers has been enthusiastic FDA clearance and CE Mark 1H Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

36 MDx MARKET SEGMENTATION BY BASE SYSTEM Biofire High GenMark Dx xtag/xmap Plex Range Low ARIES v2 Nanosphere Project ARIES Cepheid Abbott BD Hologic Roche Low Throughput * * Throughput from base model 36 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science High

37 ARIES NEXT GENERATION ADDS MULTIPLEXING CAPABILITY ARIES v2: real-time PCR + multiplexing Backwards compatible with ARIES v1 cassettes (no need to re-develop v1 assays) ARIES nucleic acid extraction unchanged 37 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

38 PIPELINE SUMMARY 1. Low-plex market: ARIES is progressing well; on track for global launch in 2014 with 5 IVD assays & LDT compatibility 2. High-plex market: Next Generation xtag RVP assay has entered development and is on track for launch in Second generation ARIES system, with both low-plex and high-plex sample to answer capabilities, is now being developed 38 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

39 EXPANDING OPPORTUNITIES IN MOLECULAR DIAGNOSTICS RUSSELL W. BRADLEY SR. VICE PRESIDENT, CORPORATE DEVELOPMENT AND GLOBAL MARKETING

40 KEY POINTS MDx Market is Attractive Luminex is well positioned for long-term growth Expanding Range of Portfolio Platforms ARIES synergistic with current Luminex products Addresses key large market segments Leveraging Core Capabilities and Technologies Track record of innovation leading to share gains 40 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

41 WORLDWIDE MDx MARKET SHOULD CONTINUE GROWING BASED ON NEED AND NEW APPLICATIONS $ in Billions $8.0 $6.0 $4.0 $2.0 $0.0 CAGR 8% Other Pharmacogenomics Inherited Disease Prenatal Tissue Typing Oncology Blood Screening Infectious Diseases Source: Market Diagnostics International (MDxI); Kalorama 2013 Report on Molecular Diagnostics and internal estimates 41 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

42 MDX INFECTIOUS DISEASE SEGMENT 2017 Total Infectious Disease 2017e MDx Market: $4.0B Percentage of Total ID Segment ($ in billions) $10.0 $8.0 Total MDx Market CAGR = 8% 3% 2% 7% STI Hepatitis HAI /C. Diff $6.0 $4.0 $2.0 22% 42% Respiratory Pathogen ID Other $ % Source: Market Diagnostics International (MDxI), Kalorama 2013 Report on Molecular Diagnostics and internal estimates 42 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

43 BUILDING ON LUMINEX S STRONG POSITION IN MOLECULAR TESTING Reference Labs Large Hospitals 1 Performs 45% of MDx Volume Performs 35% of MDx Volume Full MDx (500) Footnotes: (1) Hospitals >300 beds Limited MDx (1000) No MDx (5000) Source: Emmes Database (2013): 1,000 U.S. laboratory survey, Scientia Analysis, AHA Registered U.S. Hospitals, CMS CLIA 43 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

44 LAB DEVELOPED TEST MARKET OPPORTUNITY PROVIDING A BETTER SOLUTION TO THIS $650M MARKET Question: Of the MDx tests that you perform, what percent are LDTs? 100% 80% 60% >50% 60-70% 80% 90% 70-80% 60-70% ~95% 40% 20% 20-30% 0% Mid Atlantic NY Metro Mid America Great N.W. West Coast Southeast So California Netherlands Medical Center Hospital Source: Internal Survey of Top 100 Hospitals by Bed Size 44 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

45 THE VIRTUOUS CYCLE OF OUR LDT BUSINESS MODEL Lab 45 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

46 LAB DEVELOPED TESTS LUMINEX WELL POSITIONED TO BENEFIT FROM CUSTOMER NEEDS TO EXPAND AND SIMPLIFY LDT PROCESSES Major unmet need Significant opportunity ($650M, 20+% CAGR * ) Luminex already has a thriving LDT business Project ARIES poised to deliver automated LDTs - High revenue and margin per instrument - Sticky business - Highly differentiated offering - Competitive advantage, and sustainable - Increases likelihood of adoption of FDA cleared tests * Source: Kalorama 2013 Report on Molecular Diagnostics and internal estimates 46 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

47 LUMINEX'S SYSTEM PORTFOLIO SPANS CUSTOMER MULTIPLEXING NEEDS... Project ARIES increases Luminex s available MDx market opportunity by 4X 500-Plex MULTIPLEXING CAPABILITIES <5 Plex 500+ <10-Plex 50-Plex MAGPIX Launched Plex Luminex 200 Launched 2005 FLEXMAP 3D Launched 2009 Project ARIES SYSTEM THROUGHPUT Source: Bcc Research, Molecular Diagnostics: Technologies and Global Markets, March Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

48 ... AND LEVERAGES LUMINEX'S CHANNEL STRENGTH Reference Labs Medical Centers Inherited Diseases Infectious Disease Lab Developed LAB Tests DEVELOPED TESTS Lab Developed Tests Pharmacogenetics Project ARIES: 5 Assays + LDT ASRs ASRs ASRs 48 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

49 INNOVATION PATH CONTINUES WITH NEW SYSTEMS AND ASSAYS Project ARIES + initial assays commercialize in EU Project ARIES + initial assays cleared by FDA Project ARIES single bay & second tranche of assays cleared by FDA Project ARIES v2 next generation chemistry and cassette design 49 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

50 COMPARISON, MULTIPLEX TECHNOLOGIES 50 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

51 PROJECT ARIES CAPABILITIES Lab Developed Test Compatibility Hands On on Steps steps* LUMINEX ARIES 4 CEPHEID BD FOCUS Throughput (Samples (samples Per per Linear linear Foot foot bench Bench space) Space)* Integrated CPU CPU QC Trending (Lean Lab Principle) Source: Company specifications, CAP Today October 2013 and internal estimates * Samples per day per linear foot of bench space 51 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

52 HOW WE WIN It s not just what you build, it s how you build it. Menu Expansion Ease and Flexibility Product Performance Seamless Lab Integration Commercial Channel Control The entire customer experience builds brand loyalty. 52 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

53 CONCLUSION PATRICK BALTHROP PRESIDENT AND CEO

54 LUMINEX VALUATION CONSIDERATIONS LMNX QDEL BIO Revenue Growth ('09-'12) -2% 5% 19% LMNX QDEL BIO 2014E Revenue Growth 4% 9% 12% EV/2014E Rev. Ticker 3.2x LMNX 4.8x QDEL 1.2x BIO TMO QGEN CPHD GNMK N/A 7% 7% 25% TMO QGEN CPHD GNMK 4% 4% 12% 18% 2.9x TMO 4.2x QGEN 5.8x CPHD 14.0x GNMK -10% 0% 10% 20% 30% 0% 10% 20% Source: SEC Filings, Thomson Reuters First Call, Wall St. Research 54 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

55 LUMINEX VALUATION CONSIDERATIONS ~$ M Scarcity Pipeline ~$ M ARP TSP Sales ( 13) CAGR ( 07-12) EV/Sales EV Value Per Share Value TSP $ M 1 14% x $ M $8 12 ARP $80 90M 1 45% x $ M $ For illustration purposes only. Not to be considered guidance. Estimate derived by projecting reported 3Q 2013 YTD revenue split by segment. 55 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science Current Valuation* Rev: $212M - $217M EV/Sales: 3.3x EV Value: $700M Per Share Value $18.00 * As of market close 11/7/2013

56 LUMINEX INVESTMENT THESIS One of a kind platform technologies - Multiple products - Unmatched installed base Leadership Position in High Growth Markets Track Record of Innovation, Execution, New Products Compelling, Exciting Pipeline as Near Term Catalyst - Next generation multiplexing technology - Expected 2014 commercial launch of Project ARIES - ARIES platform product line, including ARIES v2 - ARIES menu expansion Consistent Above Market Growth and Excellent Financial Position - 70% gross margins 10 year average CAGR 20% 56 Copyright 2013 Luminex Corporation Breakthrough solutions to improve health and advance science

57 VALUING THE FUTURE OF MOLECULAR DIAGNOSTICS Q&A HYATT REGENCY, PHOENIX NOVEMBER 13, 2013